ConductScience.org, home

Paper34145166

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.

Bryant A and 6 others. Am J Ther, 2021. Cited by 157 papers, by iCite. Under an expression of concern.

Cite this record

ConductScience Library. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Papers, record 34145166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34145166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.
PubMed
Journal
Am J Ther
PubMed
Year
2021
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
157
iCite
Relative citation ratio, by iCite
9.58
iCite
Expression of concern
Yes, by PubMed's record
PubMed
Revised in PubMed
2024-04-02
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bryant AAndrewhttps://orcid.org/0000-0003-4351-8865
2Lawrie TATheresa A
3Dowswell TTherese
4Fordham EJEdmund J
5Mitchell SScott
6Hill SRSarah R
7Tham TCTony C

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
IvermectinMajor topic
COVID-19 Drug TreatmentMajor topic
Antiviral Agents
Humans
SARS-CoV-2
Treatment Outcome

Source PubMed

Download CSV of topics

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Expression of concern in35142702
Expression of Concern for Bryant a, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4): e434-e460.
https://conductscience.org/library/papers/35142702PubMed
Comment in34469921
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021.
https://conductscience.org/library/papers/34469921PubMed
Comment in34994351Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19.https://conductscience.org/library/papers/34994351PubMed

Download CSV of comments and corrections

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132678530Dexamethasone in Hospitalized Patients with Covid-19.N Engl J Med2021https://conductscience.org/library/papers/32678530PubMed
212362927Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.J Clin Pharmacol2002https://conductscience.org/library/papers/12362927PubMed
333542646Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women.Int J Gen Med2021https://conductscience.org/library/papers/33542646PubMed
432895293Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.Open Heart2020https://conductscience.org/library/papers/32895293PubMed
532378737The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19.Clin Pharmacol Ther2020https://conductscience.org/library/papers/32378737PubMed
620623822Meta-analysis for rare events.Stat Med2010https://conductscience.org/library/papers/20623822PubMed
731960060Safety of high-dose ivermectin: a systematic review and meta-analysis.J Antimicrob Chemother2020https://conductscience.org/library/papers/31960060PubMed
822143403Bayesian analysis on meta-analysis of case-control studies accounting for within-study correlation.Stat Methods Med Res2015https://conductscience.org/library/papers/22143403PubMed
934483029Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.J Infect Chemother2021https://conductscience.org/library/papers/34483029PubMed
1034265236Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.J Pharm Pharm Sci2021https://conductscience.org/library/papers/34265236PubMed
1120827667Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data.Stat Med2010https://conductscience.org/library/papers/20827667PubMed
1233454964Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality.Br J Dermatol2021https://conductscience.org/library/papers/33454964PubMed
1332942671Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?Cells2020https://conductscience.org/library/papers/32942671PubMed
143802833Meta-analysis in clinical trials.Control Clin Trials1986https://conductscience.org/library/papers/3802833PubMed
1532559771The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.Drug Res (Stuttg)2020https://conductscience.org/library/papers/32559771PubMed
1633065103Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.Chest2021https://conductscience.org/library/papers/33065103PubMed
1734249367
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.
New Microbes New Infect2021https://conductscience.org/library/papers/34249367PubMed
1833599247Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos.QJM2022https://conductscience.org/library/papers/33599247PubMed
1935314650Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial.Infect Dis Rep2022https://conductscience.org/library/papers/35314650PubMed
2031349391MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta.Res Synth Methods2019https://conductscience.org/library/papers/31349391PubMed

See all 50 referencesDownload CSV of references

Cited by124

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 157 citations.

PMIDTitleJournalYearIn PapersSource
42890391Toxicological Vulnerabilities and Emerging Safety Signals in Modified mRNA Vaccine Technology: A Narrative Review of the COVID-19 Experience.J Toxicol2026https://conductscience.org/library/papers/42890391PubMed
42426878Translational stewardship in pandemic therapeutics: ivermectin, evidentiary misalignment, and the propagation of constraints.J Transl Med2026https://conductscience.org/library/papers/42426878PubMed
41918076The role of ivermectin in the prevention and treatment of SARS-CoV-2 infection: a meta-analysis of randomized controlled trials.BMC Infect Dis2026https://conductscience.org/library/papers/41918076PubMed
41012540A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2.Pharmaceutics2025https://conductscience.org/library/papers/41012540PubMed
40723800Immune Signatures in Post-Acute Sequelae of COVID-19 (PASC) and Myalgia/Chronic Fatigue Syndrome (ME/CFS): Insights from the Fecal Microbiome and Serum Cytokine Profiles.Biomolecules2025https://conductscience.org/library/papers/40723800PubMed
40529997What Lessons can Be Learned From the Management of the COVID-19 Pandemic?Int J Public Health2025https://conductscience.org/library/papers/40529997PubMed
40426524Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole.Antibiotics (Basel)2025https://conductscience.org/library/papers/40426524PubMed
40327060Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40327060PubMed
40124821Ivermectin as a Treatment Modality in COVID-19 Patients: A Systematic Review and Meta-Analysis of Up-To-Date RCTs.Indian J Community Med2025https://conductscience.org/library/papers/40124821PubMed
40006532
Experimental Investigation into the Design, Optimization, Toxicity, and Anti-Viral Efficacy of Proliposomes Loaded with Ivermectin Against Infectious Bronchitis Virus Using an Embryonated Chicken Egg Model.
Pharmaceutics2025https://conductscience.org/library/papers/40006532PubMed
39791740The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites.Cells2025https://conductscience.org/library/papers/39791740PubMed
39744515Non-spike protein inhibition of SARS-CoV-2 by natural products through the key mediator protein ORF8.Mol Biol Res Commun2025https://conductscience.org/library/papers/39744515PubMed
39726468Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients.Cureus2024https://conductscience.org/library/papers/39726468PubMed
39706537Trial sequential analysis involving same-year studies requires careful temporal ordering.J Clin Epidemiol2025https://conductscience.org/library/papers/39706537PubMed
39654597Medical Ethics and Informed Consent to Treatment: Past, Present and Future.Cureus2024https://conductscience.org/library/papers/39654597PubMed
39460768Repositioning of Antibiotics in the Treatment of Viral Infections.Curr Microbiol2024https://conductscience.org/library/papers/39460768PubMed
39457519Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.Biomedicines2024https://conductscience.org/library/papers/39457519PubMed
39452140Unveiling the Interplay-Vitamin D and ACE-2 Molecular Interactions in Mitigating Complications and Deaths from SARS-CoV-2.Biology (Basel)2024https://conductscience.org/library/papers/39452140PubMed
39292387Following the Science in the Age of COVID-19.J Med Humanit2026https://conductscience.org/library/papers/39292387PubMed
39254115Toxicologic Pathology Forum: mRNA Vaccine Safety-Separating Fact From Fiction.Toxicol Pathol2024https://conductscience.org/library/papers/39254115PubMed

See all 124 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
CYP3A41576PubTator's text mininghttps://conductscience.org/library/genes/1576NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34145166

GET https://conductscience.org/api/papers/v1/34145166/references?page=2